Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.6% Higher – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded up 0.6% during mid-day trading on Thursday . The company traded as high as $6.53 and last traded at $6.26. 6,932,748 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 6,639,027 shares. The stock had previously closed at $6.22.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RXRX shares. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Down 2.4 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average price is $6.77 and its 200 day moving average price is $7.23. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -3.97 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the previous year, the firm posted ($0.43) EPS. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,788 shares of company stock valued at $724,691. 15.75% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter worth about $25,000. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares in the last quarter. Amalgamated Bank grew its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the period. KBC Group NV increased its position in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after buying an additional 3,377 shares in the last quarter. Finally, San Luis Wealth Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the 3rd quarter worth approximately $69,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.